The introduction of the 750mcg teriparatide formulation in Australia has seen controlled availability to date. Primarily designated for patients with severe osteoporosis who have not responded to other medications, access is selectively managed. Existing supply quantities are tight , and individuals should verify from their doctor the recent inform